

PHARMAPAR INC
BALANCE SHEET AS AT MARCH 31, 2019

		Amount in CAD
		31-Mar-19
A ASSETS		
I Non-current assets		
(a) Property, plant and equipment		407,615
(b) Financial assets		
(i) Other financial assets	1	<u>50,600</u>
Total non-current assets		458,215
I Current assets		
(a) Inventories	2	1,747,527
(b) Financial assets		
(i) Trade receivables	3	698,148
(ii) Cash and cash equivalents	4	267,901
(c) Other current assets	5	<u>68,763</u>
Total current assets		2,782,339
TOTAL ASSETS		<u><u>3,240,554</u></u>
B EQUITY AND LIABILITIES		
I Equity		
(a) Equity share capital	6	5,000,397
(b) Other equity	7	<u>(3,917,095)</u>
Total Equity		1,083,302
II Liabilities		
1 Current liabilities		
(a) Financial liabilities		
(i) Trade payables	8	1,830,679
(ii) Other financial liabilities	9	153,726
(b) Provisions	10	<u>172,848</u>
Total current liabilities		2,157,252
TOTAL EQUITY AND LIABILITIES		<u><u>3,240,554</u></u>

PHARMAPAR INC
STATEMENT OF PROFIT AND LOSS FOR THE YEAR ENDED MARCH 31, 2019

		Amount in CAD	
	Particulars	Note No.	31-Mar-19
1	Revenue from operations	11	831,847
2	Other Income	12	1,603
3	Total Revenue (1+2)		<u>833,450</u>
4	Expenses		
	(a) Purchases of stock in trade		388,374
	(b) (Increase) / Decrease in inventories of finished goods, work-in-progress and stock-in-trade		
	(b) Employee benefits expense	13	132,811
	(c) Finance costs	14	9,348
	(d) Depreciation and amortisation expense		12,133
	(e) Other expenses	15	36,775
	Total expenses		<u>579,441</u>
5	Profit / (Loss) before exceptional items and taxes (3-4)		<u>254,009</u>
6	Exceptional Item		-
7	Profit / (Loss) before taxes (5+6)		<u>254,009</u>
8	Tax Expense:		
	(1) Current tax		-
	(2) Deferred tax		-
	Total tax expenses		<u>-</u>
VII	Profit / (Loss) for the year after tax		<u>254,009</u>

PHARMAPAR INC
STATEMENT OF CHANGES IN EQUITY
FOR THE YEAR ENDED MARCH 31, 2019

(A) Equity share capital

Particulars	Amount in CAD
Balance as at March 31,2018	5,000,397
Changes in equity share capital during the year	
Balance as at March 31,2019	5,000,397

(B) Other equity

Particulars	Share application money pending allotment	Reserves and surplus	Items of other comprehensive income	Total
		Retained earnings	Re -measurement of the defined benefit liabilities / (assets)	
Balance as at March 31,2018	-	(4,171,104)	-	(22,026)
Profit/loss for the year	-	254,009	-	254,009
Other comprehensive income for the year (net of tax)	-		-	-
Balance as at March 31,2019	-	(3,917,095)	-	231,984

PHARMAPAR INC
Notes forming part of financial statement

Note
No.

1	Non current financial assets	Amount in CAD
	Particulars	31-Mar-19
	Rent Deposit	50,600
	Total	50,600
2	Inventories	Amount in CAD
	Particulars	31-Mar-19
	Stock In trade	1,747,527
	Total	1,747,527
3	Trade receivables	Amount in CAD
	Particulars	31-Mar-19
	Unsecured	
	Considered good	698,148
	Considered doubtful	-
		698,148
	Less: Allowance for doubtful trade receivables	-
	Total	698,148
4	Cash and cash equivalents	Amount in CAD
	Particulars	31-Mar-19
	Cash in hand	500
	Balances with banks:	
	In current accounts	267,401
	In deposit accounts	
	Total	267,901
5	Other current assets	Amount in CAD
	Particulars	31-Mar-19
	Unsecured, considered good	
	Loans and advances to employees	577
	Loans and advances to suppliers	7,500
	Loans and advances to Group entities	2,017
	Balances with government authorities:	-
	Prepaid Expenses	58,669
	Total	68,763
6	Share capital	Amount in CAD
	Particulars	31-Mar-19
	Issued, subscribed and fully paid-up	
	Equity share capital	5,000,397
	Preference share capital	-
	Total	5,000,397
7	Reserves and surplus	Amount in CAD
	Particulars	31-Mar-19
	Surplus in statement of profit and loss	
	Opening balance	(4,171,104)
	Add: Profit / (Loss) for the year	254,009
	Closing balance	(3,917,095)
	Total	(3,917,095)
8	Trade payables	Amount in CAD
	Particulars	31-Mar-19
	Trade payable	1,830,679
	Total	1,830,679
9	Other Current financial Liabilities	Amount in CAD
	Particulars	31-Mar-19
	Current maturities of secured term loans from banks	
	Interest accrued but not due	
	Payable to group entities	150,000
	Others	3,726
	Other payables:	
	- Statutory remittances	
	Total	153,726
10	Provisions	Amount in CAD
	Particulars	31-Mar-19
	Provisions	172,848
	Total	172,848

PHARMAPAR INC
Notes forming part of financial statement

Note

No.

11 Revenue from operations		Amount in CAD
Particulars	31-Mar-19	
Sale of Product	831,847	
Sale licensing Income		
Total		831,847

12 Other Income		Amount in CAD
Particulars	31-Mar-19	
Interest Income	1,603	
Total		1,603

13 Employee Benefit Expenses		Amount in CAD
Particulars	31-Mar-19	
Salaries and wages	98,258	
Staff Welfare	34,553	
Total		132,811

14 Finance cost		Amount in CAD
Particulars	31-Mar-19	
Other finance Cost	9,348	
Total		9,348

15 Other expenses		Amount in CAD
Particulars	31-Mar-19	
Power and fuel	2,892	
Rent	6,042	
Repairs & Maintenance	5,701	
Conveyance & Travelling	12,996	
Communication expenses	1,596	
Business promotion	5,491	
Miscellaneous Expense	2,058	
Total		36,775